# A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

> **NCT04379167** · PHASE2 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT04379167
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04379167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04379167, "A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04379167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*